Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis
Authors:
- 28 June 2019
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 110 (4) , 419-430
Abstract
Emicizumab is a bispecific antibody to factor (F) IX/IXa and FX/FXa, which mimics FVIIIa cofactor function. Emicizumab prophylaxis significantly decreases bleeding events for patients with hemophilia A (PwHA). However, global hemostatic monitoring in emicizumab-treated PwHA remains poorly investigated. Using rotational thromboelastometry (ROTEM), we evaluated coagulation potentials of whole blood samples from seven emicizumab-treated PwHA who participated in ACE001JP/ACE002JP studies. Dose-dependent coagulation-enhancing effects of emicizumab to whole blood from PwHA mixed with an anti-FVIII C2 antibody in vitro were evident by non-activated ROTEM analysis (NATEM). The relationship between FVIII levels and NATEM parameters in PwHA not participating in the clinical trials demonstrated that CT + CFT inversely correlated with FVIII levels. These parameters were defined as NATEM-based grading of coagulation potential; ‘T1’ (FVIII < 1 IU/dL), ‘T2’ (1 ≤ , < 12 IU/dL) and ‘T3’ (12 ≤ , < 60 IU/dL). Coagulation function in emicizumab-treated PwHA was determined to be ‘T2’ or ‘T3,’ and was dependent on plasma emicizumab concentration. Improvement of NATEM-based grades corresponded with significant reduction of bleeding episodes, except for target joints, and differences were due to the time to reach the coagulation-steady state in individual patients. The NATEM analysis may be useful for intra- and inter-individual evaluation of coagulation function in emicizumab-treated PwHA.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (KAKENHI)
- Ministry of Education, Culture, Sports, Science and Technology (KAKENHI)
This publication has 28 references indexed in Scilit:
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor ActivityPLOS ONE, 2013
- Clinical severity of haemophilia A: does the classification of the 1950s still stand?Haemophilia, 2011
- Identifying non‐responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definitionHaemophilia, 2010
- Mechanisms of factor VIIa‐catalyzed activation of factor VIIIJournal of Thrombosis and Haemostasis, 2010
- Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profileJournal of Thrombosis and Haemostasis, 2010
- Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed?Thrombosis and Haemostasis, 2009
- Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastographyHaemophilia, 2006
- The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assayJournal of Thrombosis and Haemostasis, 2006
- Identification of a factor VIII peptide, residues 2315–2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effectBritish Journal of Haematology, 1999
- The Role of Prothrombin Complex Concentrates In the Treatment of Hemophiliacs with Factor VIII InhibitorsScandinavian Journal of Haematology, 1984